Involvement of p38α in the mitotic progression of<i>p53<sup>-/-</sup></i>tetraploid cells
Article 2010 en
Authors
IV
Ilio Vitale
MJ
Mohamed Jèmaà
LS
Laura Senovilla
Abstract
1 min read
The tumor suppressor protein p53 plays a major role in preserving genomic stability. p53 suppresses a pathway leading from normal diploidy to neoplastic aneuploidy (via an intermediate metastable stage of tetraploidy) at two levels: first by preventing the generation/survival of tetraploid cells, and second by repressing their aberrant multipolar division. Here, we report the characterization of p53-/- tetraploid cells, which - at difference with both their p53-/- diploid and their p53+/+ tetraploid counterparts - manifest a marked hyperphosporylation of the mitogen-activated protein kinase MAPK14 (best known as p38α) that is particularly strong during mitosis. In p53-/- tetraploid cells, phosphorylated p38α accumulated at centrosomes during the metaphase and at midbodies during the telophase. Selective knockdown or pharmacological inhibition of p38α had a dramatic effect on p53-/- (but not p53+/+) tetraploids, causing the activation of the spindle assembly checkpoint, an arrest during the metaphase, a major increase in abnormal bipolar and monopolar mitoses, as well as an increment in the generation of multinuclear cells. We conclude that the mitotic progression of p53-/- (but not p53+/+) tetraploids heavily relies on p38α, revealing a novel function for this protein in the context of aneuploidizing cell divisions.
Laura Senovilla, Ilio Vitale, Lorenzo Galluzzi, Sonia Vivet, Nicholas Joza, Aména Ben Younes, Santiago Rello‐Varona, Maria Castedo, Guido Guido Kroemer
Ilio Vitale, Lorenzo Galluzzi, Sonia Vivet, Lisa Nanty, Laura Senovilla, Ken A. Olaussen, Vladimir Lazar, Roy M. Golsteyn, Maria Castedo, Guido Guido Kroemer
Ilio Vitale, Lorenzo Galluzzi, Sonia Vivet, Lisa Nanty, Philippe Dessen, Laura Senovilla, Ken A. Olaussen, Vladimir Lazar, Michelle Prudhomme, Roy M. Golsteyn, Maria Castedo, Guido Guido Kroemer
Discussion(0)
No comments yet. Be the first to comment.